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ORIGINAL INVESTIGATION
Severely impaired microvascular 
reactivity in diabetic patients with an acute 
coronary syndrome
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Abstract 
Background: Microvascular function is impaired in patients with stable coronary artery disease. The aim was to study 
microvascular function in patients with diabetes and acute coronary syndrome (ACS).
Methods: Microvascular function was evaluated in 83 patients by laser Doppler fluxmetry (LDF) [PU; perfusion unit, 
median (interquartile range)] measuring resting LDF and peak LDF following a six min heating of the skin to 44 °C at 
the foot, respectively. All patients with ACS and without previously known diabetes underwent oral glucose tolerance 
test. Thirty-nine patients with type 2 diabetes mellitus free from coronary artery disease served as controls.
Results: Peak LDF was significantly (P = 0.03) lower in patients with ACS and diabetes (n = 22; 72 (52)) and diabe-
tes without coronary artery disease (n = 39; 69 (51)) as compared to patients with ACS without diabetes (n = 46; 97 
(60)), and patients without ACS (n = 15; 140 (121)), respectively. Patients with ACS (n = 68) had significantly (P = 0.04) 
lower peak LDF (92 (49)) as compared to patients without ACS (n = 15) (140 (121)).
Conclusion: Microvascular reactivity is severely impaired in patients with diabetes and ACS. Diabetes has a major 
influence on microvascular function in patients with coronary artery disease.
Keywords: Microvascular reactivity, Coronary artery disease, Acute coronary syndrome, Diabetes mellitus,  
Laser Doppler fluxmetry
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Background
There is compelling evidence for a link between abnor-
malities of the microvascular function and the patho-
genesis of cardiovascular disease [1–4]. Furthermore, 
microcirculation is essential for adequate blood supply 
and oxygenation to tissues, in particular when exposed to 
ischaemia. Optimal microvascular reactivity in response 
to ischaemia is crucial to limit the extent of tissue injury. 
Strong associations between endothelial dysfunction in 
the peripheral circulation and both atherosclerotic risk 
and future cardiovascular events have been described. 
Most of these studies have investigated vascular function 
in the brachial artery, providing large vessel function [5–
8]. There are a few studies of peripheral blood flow, e.g., 
skeletal muscle of the calf and subcutaneous blood flow, 
in the acute phase of myocardial infarction [9, 10]. More 
recently, a few studies of skin microcirculation in patients 
with coronary artery disease have been published, show-
ing disturbed skin microcirculation in these patients [11–
14]. Furthermore, an impaired microvascular endothelial 
function has been shown in patients with early-onset 
coronary artery disease [15, 16]. A link between skin 
microcirculation and myocardial microvascular function 
has been described indicating that peripheral microcir-
culatory variables may be useful for non-invasive assess-
ment of myocardial ischaemia [17]. A potential link 
between microvascular function in the skin and in the 
myocardium facilitates studying the pathophysiology 
of myocardial microvascular dysfunction during myo-
cardial ischaemia. Impaired insulin resistance has been 
associated with coronary microcirculatory dysfunction in 
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patients with ST segment elevation myocardial infarction 
[18].
However, the influence of impaired glucose tolerance 
and/or diabetes on skin microcirculation has not been 
studied in patients with acute coronary syndrome (ACS). 
Impaired glucose tolerance or type 2 diabetes is present 
in as many as two-thirds of all patients with an ACS and 
is associated with poor clinical outcome [19, 20].
The aim of the present study was to investigate skin 
microvascular reactivity in patients with ACS, and to 
evaluate the influence of impaired glucose tolerance and/
or diabetes on skin microvascular reactivity.
Methods
Patient population
Eighty-three consecutive patients admitted to our insti-
tution with suspected coronary artery disease during 
a period of 2  months were investigated. Included were 
patients with verified or suspected ACS in need of obser-
vation in the cardiology department. Patients with unsta-
ble haemodynamic parameters, e.g., cardiogenic shock 
and uncompensated congestive heart failure, and history 
of peripheral arterial occlusive disease were excluded. 
Thirty-nine patients with type 2 diabetes mellitus free 
from coronary artery disease previously investigate in 
diabetes mellitus and diastolic dysfunction study served 
as controls [21]. An ACS was defined according to the 
European Society of Cardiology definition [22]. Diabe-
tes mellitus was defined according to the World Health 
Organization definition, and the fasting plasma glucose 
(FBG) criteria according to the American Diabetes Asso-
ciation [23]. The study protocol, conducted according to 
the declaration of Helsinki, was approved by the local 
human ethics committee of Karolinska Institutet. Oral 
and written informed consent was obtained from all 
patients.
Microcirculation and biochemical analysis
The vascular investigations were performed within 3 days 
of admission but not during the first 24 h. All investiga-
tions were performed in the morning, in the supine posi-
tion after 30 min of acclimatization. Patients were asked 
to refrain from coffee and smoking for at least 8 h before 
the investigation. Brachial systolic and diastolic blood 
pressures were measured by the Riva Rocci method. 
Ankle systolic blood pressure was measured with a pen 
Doppler device over the dorsal pedal and posterior tibial 
arteries. Arm and ankle blood pressures were measured 
three times and averaged and an ankle/brachial-index 
was calculated.
All studies of skin microvascular reactivity were con-
ducted in a temperature-controlled room (22 ± 1.0  °C). 
Following measurement of skin temperature, skin 
microcirculation was evaluated by laser Doppler Fluxme-
try (LDF) (PeriFlux 4001 Master, Perimed, Järfälla, 
Sweden) at the dorsum of the foot. Following 3  min 
measurement of resting LDF, peak skin microvascular 
vasodilatation was assessed following 6 min of heating of 
the skin under the LDF probe to 44 °C (peak LDF) (Peri-
Temp 4005 with thermostatic probe PF 457, Perimed, 
Järfälla, Sweden). Day-to-day coefficient of variation for 
peak LDF during local heating of skin to 44 °C at the foot 
level has been investigated in 5 healthy subjects at our 
laboratory and was 18 %.
Patients diagnosed with ACS and without previously 
known diabetes underwent a standardised 75-g oral glu-
cose tolerance test (OGTT) according to WHO criteria 
prior to discharge, not earlier than on day 4 following 
admission. Patients were classified as having diabetes if 
the 2-h post load plasma glucose concentration exceeded 
11.0  mmol/l. Impaired glucose tolerance (IGT) was 
defined as a 2-h post load blood glucose between 8.7 and 
11.0 mmol/l.
Fasting plasma glucose, glycated haemoglobin 
(HbA1c), total serum cholesterol, low density lipoprotein 
(LDL), high density lipoprotein (HDL) concentrations 
and triglycerides (TG) were assessed at day 3 post admis-
sion by standard methods, according to local laboratory 
routines. HbA1c was analysed by the Mono S method 
only in patients with diabetes.
Statistical analysis
Data are presented as mean values ±SD if not otherwise 
stated. Microcirculation data are expressed as medians 
and interquartile range. Group comparisons were made 
by the Mann–Whitney rank sum test and the Kruskal–
Wallis test. Associations were assessed by the Spearman 
rank correlation. A two-sided probability (P) value <0.05 
was considered significant.
Results
The basal characteristics of the 83 admitted patients, 
divided according to the presence of ACS and dia-
betes, and 39 patients with type 2 diabetes free from 
coronary artery disease are shown in Table  1. An 
ACS was confirmed in 68 admitted patients. Of these, 
21 patients had a known type 2 diabetes, and of the 
remaining 47 patients who underwent OGTT, one 
patient was diagnosed with type 2 diabetes and ten 
with IGT. None of the patients had type 1 diabetes. 
The 15 patients without ACS had all normal fasting 
plasma glucose levels. These patients had no evidence 
of significant coronary artery disease. All patients were 
in NYHA class I. There was a trend for higher age and 
serum creatinine levels in patients with ACS, as com-
pared to those without ACS. Patients with ACS and 
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diabetes had higher body mass index, as compared to 
other groups, while levels of total cholesterol and LDL 
were lower in patients with ACS and diabetes. Statin 
therapy was more common in patients with diabetes 
(data not shown).
All patients had stable haemodynamic measures, with-
out any signs of cardiogenic shock or decompensated 
heart failure at the time of admission and/or vascular 
investigations.
Ankle blood pressure was lower in patients with 
ACS, as compared to patients without ACS, while there 
were no significant differences in ankle/brachial-index 
between the groups.
The results of the investigations of skin microvascu-
lar reactivity are presented in Fig. 1. There were no sig-
nificant differences in resting LDF between the groups 
(Fig. 1a). Significantly lower peak LDF was measured in 
patients with ACS and diabetes and patients with dia-
betes free from CAD, respectively, compared to patients 
with ACS without diabetes and patients without ACS 
(Fig. 1b). The highest peak LDF was found in the patients 
without ACS and no diabetes (Fig.  1b). In the ten 
patients with ACS and IGT, peak LDF was 101 (75) PU, 
as compared to 72 (52) PU in 22 patients with diabetes 
(P  =  0.07). There were no differences in skin tempera-
ture between the groups (data not shown). A weak nega-
tive correlation (r = −0.22; P = 0.05) was found between 
body mass index and peak LDF. Age, blood lipids, fasting 
plasma glucose, HbA1c, brachial or ankle systolic blood 
pressure did not relate to peak LDF.
Discussion
We found that microvascular reactivity is impaired in 
patients with ACS, and that the impairment is more pro-
nounced in patients with ACS and concomitant type 2 diabe-
tes. Interestingly, data from patients with diabetes free from 
CAD showed same degree of microvascular dysfunction as 
in patients with ACS and diabetes. These findings indicate 
that diabetes plays a major role in the pathogenesis of micro-
vascular dysfunction, irrespective of presence of CAD.
It has been demonstrated in previous studies that func-
tional disturbances in the microvasculature of patients 
with diabetes is characterised by reduced vasodilatory 
capacity and impaired nutritive capillary circulation [24, 
25]. Vascular endothelial dysfunction, which is closely 
linked to diabetes and impaired insulin sensitivity, may 
be a contributing factor to impaired microvascular reac-
tivity. Disturbed microvascular function is important for 
the diabetes specific complications including diabetic 
cardiomyopathy [26]. Impaired microvascular reactiv-
ity may cause disturbed myocardial perfusion in patients 
undergoing percutaneous coronary intervention (PCI) 
for myocardial infarction [27, 28], which may contribute 
to poor prognosis in these patients [20].
In the present study, the impairment of microvascu-
lar reactivity was more pronounced in patients with 
Table 1 Baseline characteristics of  83 patients divided into  three groups according to  presence of  acute coronary syn-
drome (ACS) and diabetes (DM), and 39 patients with diabetes mellitus free from coronary artery disease (CAD)
Data are presented as mean values ±SD or number of patients
HbA1c glycated haemoglobin, LDL low density lipoprotein, HDL high density lipoprotein, TG triglycerides
vs ACS+/DM+, a P < 0.05; vs ACS+/DM−, b P < 0.05; vs ACS−/DM−, c P < 0.05
ACS+/DM+ ACS+/DM− ACS−/DM− ACS−/DM+ P
n 22 46 15 39
Age (years) 71 ± 10 72 ± 11 65 ± 12 61 ± 18a, b 0.03
Male/female 11/11 32/14 9/6 16/23
Diabetes duration (years) 12 ± 9 – – 6 ± 4 0.05
Fasting plasma glucose (mmol/L) 7.8 ± 1.2 5.4 ± 0.8a 5.2 ± 0.7a 7.6 ± 1.4b, c 0.02
HbA1c (%) 6.8 ± 1.3 – – 5.9 ± 1.6a 0.04
Smoker/ex-smoker 0/10 8/25 3/8 3/9
S-creatinine (µmol/L) 110 ± 44 98 ± 33 85 ±± 17 90 ± 30 0.07
Brachial systolic blood pressure (mm Hg) 118 ± 24 115 ± 22 113 ± 24 143 ± 15a, b, c 0.02
Ankle blood pressure (mm Hg) 128 ± 37 117 ± 38 142 ± 28 157 ± 20a, b 0.03
Ankle brachial index 1.1 ± 0.4 1.1 ± 0.5 1.3 ± 0.4 1.1 ± 0.4 0.06
Body mass index (kg/m2) 31 ± 3 25 ± 3a 28 ± 3 27 ± 7a 0.01
Total cholesterol (mmol/L) 3.9 ± 0.8 4.5 ± 1.3 5.0 ± 1.0a 4.7 ± 1.0a 0.02
LDL (mmol/L) 2.0 ± 0.6 2.6 ± 1.2 3.2 ± 1.0a 2.7 ± 0.9 0.01
HDL (mmol/L) 1.0 ± 0.2 1.2 ± 0.4 1.3 ± 0.3a 1.0 ± 0.3c 0.01
Triglycerides (mmol/L) 2.1 ± 1.2 1.3 ± 0.7a 1.3 ± 0.5a 1.4 ± 0.8a 0.01
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diabetes, with or without ACS, as compared to patients 
without diabetes. In addition to acute endothelial 
dysfunction due to an ACS, hyperglycaemia per se 
may promote platelet activation, augment plugging 
of blood cells in the capillaries and thrombus forma-
tion in the capillaries, leading to further impairment 
of microvascular function [29–31]. Increased levels of 
vasoactive peptides, e.g., endothelin-1, in patients with 
diabetes might further impair microvascular reactiv-
ity in these patients. The production and plasma levels 
of endothelin-1 are elevated in patients with diabetes, 
and a positive correlation between plasma endothe-
lin-1 levels and diabetic microangiopathy has been 
described [32].
Patients with ACS had lower ankle blood pressure than 
patients without ACS indicating presence of systemic 
atherosclerosis. However, ABI was not different between 
the groups. An association between peripheral arterial 
disease and skin microcirculation has been described 
[33], but in the present study, there was no correlation 
between ankle blood pressure or ABI and peak LDF.
We have previously shown a relation between insulin 
sensitivity and skin microvascular reactivity [34, 35]. Insu-
lin sensitivity is usually related to body mass index (BMI), 
and the highest BMI in this study was found in patients 
with ACS and diabetes, which might have influenced the 
microcirculation in these patients. A non significant nega-
tive correlation between BMI and peak LDF was found in 
this study. We have recently shown that statin treatment 
improves microvascular reactivity in patients with coro-
nary artery disease and dysglycaemia [34]. The microvas-
cular dysfunction in patients with ACS and diabetes might 
be even more profound than we have demonstrated in 
this study since more patients with ACS were on statins.
We studied microvascular function by LDF, a measure 
of total skin microcirculation, i.e., nutritional capillary 
blood flow and non-nutritional sub papillary blood flow. 
An impaired skin maximum hyperaemic response to 
local heating has been observed in patients with diabetes, 
and it is associated with macro- and microvascular com-
plications and increased cardiovascular risk [1, 36]. The 
maximum microvascular hyperaemic response to local 
heating and arterial occlusion is likely to involve neuro-
genic and endothelium-dependent mechanisms induced 
by structural changes in the vessel wall [37].
There are limitations to this study. The study is small, 
and in particular the number of patients with no ACS 
was low in comparison with the other groups. Thus, care 
should be taken when the results are assessed. Further-
more, there was no group with stable coronary artery 
disease and diabetes to reveal the importance of an ACS 
for microvascular function. A methodological limitation 
is high coefficient of variability for LDF as compared to 
more recent techniques to study skin microcirculation 
such as laser speckle contrast imaging [38–40].
In conclusion, skin microvascular reactivity is impaired 
in patients with ACS, and the impairment is more pro-
nounced in patients with concomitant diabetes. Diabe-
tes alone has a major impact on microvascular function. 
A disturbed microvascular function may contribute to 
impaired myocardial perfusion during ischaemic events 
and/or PCI. None-invasive methods such as LDF to 
assess microvascular reactivity are promising tools when 
new treatment strategies to improve vascular function in 
patients with coronary artery disease are investigated.
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Fig. 1 Resting laser Doppler fluxmetry (a) and post reactive hyper-
aemia (peak LDF) (b) in patients with ACS and diabetes (ACS+/DM+; 
n = 22), ACS without diabetes (ACS+/DM−; n = 46), no ACS and no 
diabetes (ACS−/DM−; n = 15), and diabetes without coronary artery 
disease (ACS−/DM+; n = 39). Data are depicted as median and 
quartiles. PU perfusion unit
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